GlaxoSmithKline wins approval for HIV pill

GlaxoSmithKline Plc has won US regulatory approval for a daily pill against the deadly HIV infection that was developed by ViiV Healthcare Ltd, its joint venture with two other drugmakers.

Glaxo’s Tivicay can be used by adults with HIV who have never been treated for the virus and those who have previously received drugs to attack the illness.

The medicine, known as dolutegravir, interferes with the enzymes necessary for HIV to multiply, the Food and Drug Administration said in a statement.